Similarly, the Kv1.3 specific blocker PAP‐1 was recently shown to reduce neuroinflammation, Aβ plaque load and to improve behavioural deficits in a transgenic‐mouse model of AD, a disorder characterized by Kv1.3 upregulation in microglia (Figure 1) (Maezawa et al., 2011; Rangaraju, Gearing, Jin, & Levey, 2015). This evidence concerns the gene KCNA3 and Alzheimer disease.